Pazopanib shows better quality-of-life in advanced kidney cancer – Two oral targeted drugs — Pazopanib (Votrient) and sunitinib (Sutent) — approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, the safety profile and many measures of quality of life favored pazopanib.
Research provides new kidney cancer clues — Gene is mutated in 1 in 3 patients with common form of renal cancer – Researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer. The identification of a frequently mutated gene will provide new insights into the biology of the disease.
For some women, preventive mastectomies pay off — Study shows women with BRCA1 and BRCA2 genetic mutations significantly reduce their risk of breast and ovarian cancer with preventive surgeries – A long-term study of women with a genetic predisposition for breast or ovarian cancer showed that those who elected major preventive surgeries had a significantly reduced risk of those cancers.
LIN28, which maintains cell ‘stemness,’ is abundant in advanced cancers and transforms cells to cancerous state – A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children’s Hospital Boston.
Getting down to cancer basics — Cancer mutations in the heart of gene regulation. – Researchers have identified a new cancer gene – one that is common to many cancers and affects the most basic regulation of our genes.
Smoking during pregnancy increases a child?s likelihood of developing cancer. – New research by the Cancer Institute NSW has provided the strongest indication yet that smoking during pregnancy increases a child’s likelihood of developing cancer.
Anticancer drug Nexavar raised survival period in inoperable hepatocellular carcinoma patients suffering from this kind of liver cancer. – The U.S. Food and Drug Administration has approved Nexavar (sorafenib) for use in patients with a form of liver cancer known as hepatocellular carcinoma, when the cancer is inoperable. Nexavar was originally approved in 2005 for the treatment of patients with advanced renal cell carcinoma, a form of kidney cancer.